In the B16 melanoma model, intratumoral application of low-dose AZA without direct cytotoxic effects did increase transcriptional activity of both Ripk3 and Mlkl in tumor cells in vivo (figure 5A and online supplemental figure S6D). This evidence concerns the gene MLKL and neoplasm.